Aileron Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.53
- Today's High:
- $1.6623
- Open Price:
- $1.53
- 52W Low:
- $1.29
- 52W High:
- $15
- Prev. Close:
- $1.55
- Volume:
- 11895
Company Statistics
- Market Cap.:
- $6.74 million
- Book Value:
- 4.998
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-17008000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -45.37%
- Return on Equity TTM:
- -81.26%
Company Profile
Aileron Therapeutics Inc had its IPO on 2017-06-29 under the ticker symbol ALRN.
The company operates in the Healthcare sector and Biotechnology industry. Aileron Therapeutics Inc has a staff strength of 9 employees.
Stock update
Shares of Aileron Therapeutics Inc opened at $1.53 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.53 - $1.66, and closed at $1.61.
This is a +3.81% increase from the previous day's closing price.
A total volume of 11,895 shares were traded at the close of the day’s session.
In the last one week, shares of Aileron Therapeutics Inc have slipped by -3.07%.
Aileron Therapeutics Inc's Key Ratios
Aileron Therapeutics Inc has a market cap of $6.74 million, indicating a price to book ratio of 0.5022 and a price to sales ratio of 0.
In the last 12-months Aileron Therapeutics Inc’s revenue was $0 with a gross profit of $-17008000 and an EBITDA of $-29594000. The EBITDA ratio measures Aileron Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aileron Therapeutics Inc’s operating margin was 0% while its return on assets stood at -45.37% with a return of equity of -81.26%.
In Q3, Aileron Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Aileron Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-7.38 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aileron Therapeutics Inc’s profitability.
Aileron Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.4735. Its price to sales ratio in the trailing 12-months stood at 0.
Aileron Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $27.23 million
- Total Liabilities
- $4.54 million
- Operating Cash Flow
- $4.18 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Aileron Therapeutics Inc ended 2024 with $27.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $27.23 million while shareholder equity stood at $22.70 million.
Aileron Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.54 million in other current liabilities, 91000.00 in common stock, $-268238000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4.84 million and cash and short-term investments were $25.48 million. The company’s total short-term debt was $67,000 while long-term debt stood at $0.
Aileron Therapeutics Inc’s total current assets stands at $27.05 million while long-term investments were $0 and short-term investments were $20.64 million. Its net receivables were $0 compared to accounts payable of $945000.00 and inventory worth $0.
In 2024, Aileron Therapeutics Inc's operating cash flow was $4.18 million while its capital expenditure stood at $0.
Comparatively, Aileron Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.61
- 52-Week High
- $15
- 52-Week Low
- $1.29
- Analyst Target Price
- $40
Aileron Therapeutics Inc stock is currently trading at $1.61 per share. It touched a 52-week high of $15 and a 52-week low of $15. Analysts tracking the stock have a 12-month average target price of $40.
Its 50-day moving average was $1.73 and 200-day moving average was $1.9 The short ratio stood at 1.55 indicating a short percent outstanding of 0%.
Around 902.2% of the company’s stock are held by insiders while 2993.1% are held by institutions.
Frequently Asked Questions About Aileron Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.